Metagenomi (NASDAQ:MGX) Cut to Neutral at JPMorgan Chase & Co.

JPMorgan Chase & Co. cut shares of Metagenomi (NASDAQ:MGX – Free Report) from an overweight rating to a neutral rating in a research report report published on Thursday morning, MarketBeat.com reports. They currently have $6.00 price objective on the stock, down from their previous price objective of $16.00. Several other brokerages also recently commented on […]

Related Keywords

United States , ,Securities Exchange Commission ,Jpmorgan Chase Co ,Jefferies Financial Group ,Metagenomi Inc ,Wells Fargo Company ,Holdingsas Novo ,Free Report ,Financial Group ,Wells Fargo ,Moderate Buy ,Exchange Commission ,Get Free Report ,Metagenomi Daily ,Metagenomi ,Nasdaq Mgx ,Nmgx ,Medical ,Downgrade ,